KRAS and non-small cell lung carcinoma: For instance, in an Irish study on 2052 NSCLC patients, actionable genetic alterations were found in 53% of cases, with the highest rate of KRAS mutation reported to be 32%, while the rate of EGFR mutation was only 8.8%, and ALK rearrangements were found in only 2.1% cases (32).